Unknown

Dataset Information

0

High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy.


ABSTRACT: Background:Botulinum neurotoxin therapy (BoNT) is a powerful tool for treating many neurologic disorders. The U.S. Food and Drug Administration (FDA)-approved maximum onabotulinum toxin A (OnaA) dose is 400 units (U) per visit, but higher doses are commonly necessary, particularly when treating multiple body regions. Methods:We collected demographics, OnaA dose, body regions injected and indications, patient-reported efficacy via 7-point Clinical Global Impression Scale (CGIS), and duration of benefit. Results:Sixty-eight patients were identified receiving OnaA >400 U/session. Dystonia (n = 44) and spasticity (n = 24) were the most common indications for high-dose OnaA. Mean duration of benefit was 9 weeks (standard deviation [SD] 3). More than 70% of patients self-reported "very much improved" or "much improved" at 6 month, 1 year, and last visit. No serious adverse effects were reported. Discussion:The majority of patients tolerated >400 U OnaA with continued benefit. OnaA doses >400 U may be safe and effective in appropriate patients.

SUBMITTER: Chiu SY 

PROVIDER: S-EPMC7052428 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy.

Chiu Shannon Y SY   Patel Bhavana B   Burns Matthew R MR   Legacy Joseph J   Wagle Shukla Aparna A   Ramirez-Zamora Adolfo A   Deeb Wissam W   Malaty Irene A IA  

Tremor and other hyperkinetic movements (New York, N.Y.) 20200227


<h4>Background</h4>Botulinum neurotoxin therapy (BoNT) is a powerful tool for treating many neurologic disorders. The U.S. Food and Drug Administration (FDA)-approved maximum onabotulinum toxin A (OnaA) dose is 400 units (U) per visit, but higher doses are commonly necessary, particularly when treating multiple body regions.<h4>Methods</h4>We collected demographics, OnaA dose, body regions injected and indications, patient-reported efficacy via 7-point Clinical Global Impression Scale (CGIS), an  ...[more]

Similar Datasets

| S-EPMC3640534 | biostudies-other
| S-EPMC6497242 | biostudies-literature
| S-EPMC3629862 | biostudies-literature
2018-04-21 | E-MTAB-6246 | biostudies-arrayexpress
| S-EPMC5215498 | biostudies-literature
| S-EPMC8234518 | biostudies-literature
| S-EPMC5418980 | biostudies-literature
| S-EPMC6475544 | biostudies-literature
| S-EPMC4505726 | biostudies-literature
| S-EPMC10800833 | biostudies-literature